Literature DB >> 17310388

Decreased prepulse inhibition and increased sensitivity to muscarinic, but not dopaminergic drugs in M5 muscarinic acetylcholine receptor knockout mice.

Morgane Thomsen1, Gitta Wörtwein, Anders Fink-Jensen, David P D Woldbye, Jürgen Wess, S Barak Caine.   

Abstract

RATIONALE: Schizophrenic patients show decreased measures of sensorimotor gating, such as prepulse inhibition of startle (PPI). In preclinical models, these measures may be used to predict antipsychotic activity. While current antipsychotic drugs act largely at dopamine receptors, the muscarinic acetylcholine receptors offer promising novel pharmacotherapy targets. Of these, the M(5) receptor gene was recently implicated in susceptibility to schizophrenia. Due to the lack of selective ligands, muscarinic receptor knockout mice have been generated to elucidate the roles of the five receptor subtypes (M(1)-M(5)).
OBJECTIVES: Here, we used M(5) receptor knockout (M(5)-/-) mice to investigate the involvement of M(5) receptors in behavioral measures pertinent to schizophrenia. We tested the hypothesis that disruption of M(5) receptors affected PPI or the effects of muscarinic or dopaminergic agents in PPI or psychomotor stimulation.
MATERIALS AND METHODS: We measured PPI in M(5)-/-, heterozygous and wild-type mice without drugs, and with clozapine (0.56-3.2 mg/kg) or haloperidol (0.32-3.2 mg/kg) alone, and as pretreatment to D: -amphetamine. In addition, we evaluated locomotor stimulation by the muscarinic antagonist trihexyphenidyl (0.56-56 mg/kg) and by cocaine (3.2-56 mg/kg).
RESULTS: The M(5)-/- mice showed decreased PPI relative to wild-type mice, and clozapine appeared to reduce this difference, while haloperidol increased PPI regardless of genotype. The M(5)-/- mice also showed more locomotor stimulation by trihexyphenidyl than wild-type mice, while cocaine had similar effects between genotypes.
CONCLUSIONS: These data suggest that disruption of the M(5) receptor gene affected sensorimotor gating mechanisms, increased sensitivity to clozapine and to the psychostimulant effects of muscarinic antagonists without modifying the effect of dopaminergic drugs.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17310388     DOI: 10.1007/s00213-006-0682-y

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.415


  88 in total

1.  Phenotypical characterization of the rat striatal neurons expressing muscarinic receptor genes.

Authors:  V Bernard; E Normand; B Bloch
Journal:  J Neurosci       Date:  1992-09       Impact factor: 6.167

2.  Cholinergic input to dopaminergic neurons in the substantia nigra: a double immunocytochemical study.

Authors:  J P Bolam; C M Francis; Z Henderson
Journal:  Neuroscience       Date:  1991       Impact factor: 3.590

3.  An open-labeled trial of adjunctive donepezil for cognitive impairments in patients with schizophrenia.

Authors:  Robert W Buchanan; Ann Summerfelt; Cenk Tek; James Gold
Journal:  Schizophr Res       Date:  2003-01-01       Impact factor: 4.939

4.  Disruption of the prepulse inhibition of the startle reflex in vasopressin V1b receptor knockout mice: reversal by antipsychotic drugs.

Authors:  Nobuaki Egashira; Akito Tanoue; Fuminori Higashihara; Hiroko Fuchigami; Kazunori Sano; Kenichi Mishima; Yoshihiko Fukue; Hiroshi Nagai; Yukio Takano; Gozoh Tsujimoto; Jeanne Stemmelin; Guy Griebel; Katsunori Iwasaki; Tomoaki Ikeda; Ryoji Nishimura; Michihiro Fujiwara
Journal:  Neuropsychopharmacology       Date:  2005-11       Impact factor: 7.853

5.  Xanomeline, an M(1)/M(4) preferring muscarinic cholinergic receptor agonist, produces antipsychotic-like activity in rats and mice.

Authors:  H E Shannon; K Rasmussen; F P Bymaster; J C Hart; S C Peters; M D Swedberg; L Jeppesen; M J Sheardown; P Sauerberg; A Fink-Jensen
Journal:  Schizophr Res       Date:  2000-05-05       Impact factor: 4.939

Review 6.  Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies.

Authors:  D L Braff; M A Geyer; N R Swerdlow
Journal:  Psychopharmacology (Berl)       Date:  2001-07       Impact factor: 4.530

7.  The muscarinic receptor agonist xanomeline has an antipsychotic-like profile in the rat.

Authors:  K J Stanhope; N R Mirza; M J Bickerdike; J L Bright; N R Harrington; M B Hesselink; G A Kennett; S Lightowler; M J Sheardown; R Syed; R L Upton; G Wadsworth; S M Weiss; A Wyatt
Journal:  J Pharmacol Exp Ther       Date:  2001-11       Impact factor: 4.030

8.  Human serial learning: enhancement with arecholine and choline impairment with scopolamine.

Authors:  N Sitaram; H Weingartner; J C Gillin
Journal:  Science       Date:  1978-07-21       Impact factor: 47.728

9.  Central muscarinic acetylcholine receptor availability in patients treated with clozapine.

Authors:  Thomas J Raedler; Michael B Knable; Douglas W Jones; Richard A Urbina; Michael F Egan; Daniel R Weinberger
Journal:  Neuropsychopharmacology       Date:  2003-06-11       Impact factor: 7.853

Review 10.  Hallucinogens and dissociative agents naturally growing in the United States.

Authors:  John H Halpern
Journal:  Pharmacol Ther       Date:  2004-05       Impact factor: 12.310

View more
  22 in total

Review 1.  Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia.

Authors:  Carrie K Jones; Nellie Byun; Michael Bubser
Journal:  Neuropsychopharmacology       Date:  2011-09-28       Impact factor: 7.853

2.  Predictors of smoking reduction outcomes in a sample of 287 patients with schizophrenia spectrum disorders.

Authors:  Bo-Jian Wu; Tsuo-Hung Lan
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2015-08-27       Impact factor: 5.270

3.  Effects of muscarinic receptor antagonists on cocaine discrimination in wild-type mice and in muscarinic receptor M1, M2, and M4 receptor knockout mice.

Authors:  Lauren Joseph; Morgane Thomsen
Journal:  Behav Brain Res       Date:  2017-04-22       Impact factor: 3.332

Review 4.  Emerging approaches for treatment of schizophrenia: modulation of cholinergic signaling.

Authors:  Daniel J Foster; Carrie K Jones; P Jeffrey Conn
Journal:  Discov Med       Date:  2012-12       Impact factor: 2.970

5.  Muscarinic Acetylcholine Receptor Subtypes as Potential Drug Targets for the Treatment of Schizophrenia, Drug Abuse and Parkinson's Disease.

Authors:  Ditte Dencker; Morgane Thomsen; Gitta Wörtwein; Pia Weikop; Yinghong Cui; Jongrye Jeon; Jürgen Wess; Anders Fink-Jensen
Journal:  ACS Chem Neurosci       Date:  2012       Impact factor: 4.418

6.  M5 receptor activation produces opposing physiological outcomes in dopamine neurons depending on the receptor's location.

Authors:  Daniel J Foster; Patrick R Gentry; Jose E Lizardi-Ortiz; Thomas M Bridges; Michael R Wood; Colleen M Niswender; David Sulzer; Craig W Lindsley; Zixiu Xiang; P Jeffrey Conn
Journal:  J Neurosci       Date:  2014-02-26       Impact factor: 6.167

7.  Reversal of scopolamine-induced disruption of prepulse inhibition by clozapine in mice.

Authors:  Philipp Singer; Benjamin K Yee
Journal:  Pharmacol Biochem Behav       Date:  2011-12-21       Impact factor: 3.533

Review 8.  Physiological roles of CNS muscarinic receptors gained from knockout mice.

Authors:  Morgane Thomsen; Gunnar Sørensen; Ditte Dencker
Journal:  Neuropharmacology       Date:  2017-09-11       Impact factor: 5.250

9.  Modulation of prepulse inhibition through both M(1) and M (4) muscarinic receptors in mice.

Authors:  Morgane Thomsen; Jürgen Wess; Brian S Fulton; Anders Fink-Jensen; S Barak Caine
Journal:  Psychopharmacology (Berl)       Date:  2009-12-15       Impact factor: 4.530

Review 10.  Realistic expectations of prepulse inhibition in translational models for schizophrenia research.

Authors:  Neal R Swerdlow; Martin Weber; Ying Qu; Gregory A Light; David L Braff
Journal:  Psychopharmacology (Berl)       Date:  2008-06-21       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.